Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Karen M. Anderson sold 30,526 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $19.03, for a total transaction of $580,909.78. Following the sale, the insider now owns 54,322 shares of the company's stock, valued at $1,033,747.66. This trade represents a 35.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Centessa Pharmaceuticals Price Performance
CNTA opened at $17.79 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The stock has a market capitalization of $2.35 billion, a P/E ratio of -11.63 and a beta of 1.53. The company's 50 day simple moving average is $16.78 and its 200-day simple moving average is $15.49. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. Sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Centessa Pharmaceuticals
Large investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its holdings in Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after purchasing an additional 5,316 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after buying an additional 865 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Centessa Pharmaceuticals by 1,969.2% during the third quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company's stock worth $2,173,000 after buying an additional 129,335 shares during the last quarter. Lord Abbett & CO. LLC acquired a new position in Centessa Pharmaceuticals in the third quarter valued at approximately $4,305,000. Finally, Franklin Resources Inc. boosted its stake in Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock valued at $38,360,000 after acquiring an additional 1,145,823 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on CNTA. Guggenheim reaffirmed a "buy" rating on shares of Centessa Pharmaceuticals in a report on Monday. TD Cowen assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $25.83.
Read Our Latest Stock Analysis on CNTA
Centessa Pharmaceuticals Company Profile
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
